CYBN:CC News and Press, CYBIN INC. From 03/02/23

- Cybin CEO, Doug Drysdale and Wellness Icon Deepak Chopra to be featured on panel titled Open Minds: Innovations in Consciousness, Psychedelics & Mental Health - Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a bio...

Cybin (NEO: CYBN) (NYSE American: CYBN ),a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its two lead clinical development programs: CYB003, a proprietary deuterated psilocybin analog for the potential treatment of major depressive disorde...

- CYB003 Phase 1/2a interim data demonstrate rapid and short-acting effects; robust psychedelic effects at low doses; positive safety and tolerability profile; top-line efficacy data expected late Q3 2023 - - Initial findings from Phase 1 CYB004-E study suggest IV DMT was well-tolerated; ...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a strategic plan designed to streamline efforts, maximize operating efficiency and focus on critical clinical trials, including near-term, mid-term and...

- Company streamlining to fully focus on achieving near-term, mid-term and long-term clinical milestones - This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplement dated August 8, 2022 to its short form base shelf...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its third quarter performance as well as recent business highlights; the report is for the period ended Dec. 31, 2022. In the report, the company not...

- Company to provide CYB003 Phase 1/2a interim study readout and update on its CYB004 program at upcoming R&D Day on February 28, 2023 - This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplement dated August ...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received key approval to initiate human dosing of CYB004, its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule, through a protocol am...

- Marks first ever trial to evaluate deuterated DMT in humans – - Based on preclinical studies CYB004 demonstrated superior bioavailability compared to IV DMT which may support less invasive dosing methods - - CYB004 is a patented proprietary molecule protected through ...

Palm Beach, FL – January 26, 2023 – FinancialNewsMedia.com News Commentary – Even during the recent global supply chain problems, certain markets have continued to show growth. The psychedelic drugs markets is one of these continually expanding markets. Psychedeli...